Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
about
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patientsGenital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data.Conformational analysis, molecular structure and solid state simulation of the antiviral drug acyclovir (zovirax) using density functional theory methods.Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture.Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial.Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations.Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherenceDaily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency.The relationships among social support and quality of life in persons living with HIV/AIDS in Jiangxi and Zhejiang provinces, China.The herpes simplex virus type 1 latency associated transcript locus is required for the maintenance of reactivation competent latent infections.Herpes simplex virus genital infections: current concepts.
P2860
Q24194490-71240C6B-0866-42E1-BC13-A7160B4F0D16Q33750736-CF47DB50-5A41-4CF2-AAEE-4CA825A54416Q33833712-A1046B61-4052-49FB-8E33-572262542BCEQ33983315-75889979-82B5-4652-B050-77A5CECDD5B2Q34190321-10D23415-B495-4E2A-B4EB-57CC7F959031Q34244796-9BC1CE10-01A1-415A-A8FF-E47D375316E5Q35630400-32C26E8F-1B8A-4676-9175-B93937B3B77DQ35941348-480DB4E8-CE38-4A78-BAD6-086205AED8CCQ36440266-40078AA0-2934-453A-B68D-610CF6B0B495Q37042078-E8859A70-6DDF-4CBC-A064-940438975838Q37212998-988F2D0A-855F-4500-B6F1-FC7A6815078BQ39769235-3496B3AC-3AE3-4477-B782-EF43ADF99EC4Q41471416-32C73D76-5473-438A-B9BB-87FF56FA956FQ42589791-AC640A6C-3A9C-4BCA-B5DE-D5E34B9A00D4Q45363913-7B1A43F3-63FD-429E-9954-6D3010DF1EFA
P2860
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical and virologic efficac ...... multicontinent clinical trial.
@ast
Clinical and virologic efficac ...... multicontinent clinical trial.
@en
type
label
Clinical and virologic efficac ...... multicontinent clinical trial.
@ast
Clinical and virologic efficac ...... multicontinent clinical trial.
@en
prefLabel
Clinical and virologic efficac ...... multicontinent clinical trial.
@ast
Clinical and virologic efficac ...... multicontinent clinical trial.
@en
P2093
P2860
P50
P356
P1476
Clinical and virologic efficac ...... multicontinent clinical trial.
@en
P2093
HIV Prevention Trials Network 039 Protocol Team
James Hughes
Jonathan Fuchs
Jorge Sanchez
P2860
P304
P356
10.1086/651381
P407
P577
2010-04-01T00:00:00Z